Sara Jablonski, DVM, PhD, DACVIM (SAIM): No financial relationships to disclose
Despite being first described in the dog about 60 years ago, canine protein-losing enteropathy is not well understood, and there is no clear consensus on optimal therapeutic strategies. Additionally, approximately 50% of dogs do not respond well to traditional therapies. Thus, scrutiny of the evidence behind our current therapeutic management strategies and consideration of alternative approaches is necessary to advance our understanding of the disease and improve patient outcomes. In this session, the presenter will provide an overview of the evidence for current therapeutic strategies in cases of PLE. In addition, the presenter will share information from recently published and active, ongoing research as well as examples from clinical cases to illustrate how different treatment approaches may be beneficial in individual cases of PLE. Finally, we will cover newly available veterinary products that may be beneficial in the treatment of PLE.
Learning Objectives:
Upon completion of the session, the participant will have a thorough understanding of the historical evidence behind treatment strategies in dogs with protein-losing enteropathies.
The participant will be able to describe recent advances in our understanding of various treatment approaches in dogs with PLE.
Upon completion of this session, the participant will be able to describe alternative treatment approaches and newly available veterinary products for dogs with PLE.
.jpg "Sara Jablonski, DVM, PhD, DACVIM (SAIM) photo")